Journal
BIOMEDICINES
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10123232
Keywords
pluripotent stem cells; human induced pluripotent stem cells; kidney disease; autosomal dominant kidney disease; SARS-CoV-2 infection
Categories
Funding
- Ministry of Science and Technology
- Kaohsiung Medical University
- Kaohsiung Medical University Hospital
- [MOST 111-2314-B-037-062]
- [KMU-TC111A02-6]
- [KMU-Q111005]
- [KMUH 110-011]
Ask authors/readers for more resources
Human induced pluripotent stem cells (iPSCs) have opened up a wide range of opportunities for research and potential therapeutic uses since their discovery in 2007. This review examines the development of iPSC reprogramming and characterization technologies, provides an updated list of stem cell biobanks, and highlights important iPSC-based research on diseases such as autosomal dominant kidney disease and SARS-CoV-2 kidney involvement. The review also discusses challenges and future perspectives.
Human induced pluripotent stem cells (iPSCs), since their discovery in 2007, open a broad array of opportunities for research and potential therapeutic uses. The substantial progress in iPSC reprogramming, maintenance, differentiation, and characterization technologies since then has supported their applications from disease modeling and preclinical experimental platforms to the initiation of cell therapies. In this review, we started with a background introduction about stem cells and the discovery of iPSCs, examined the developing technologies in reprogramming and characterization, and provided the updated list of stem cell biobanks. We highlighted several important iPSC-based research including that on autosomal dominant kidney disease and SARS-CoV-2 kidney involvement and discussed challenges and future perspectives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available